Inhibition of the sodium-glucose cotransporter 2 (SGLT2) by canagliflozin in type 2 diabetes mellitus results in large between-patient variability in clinical response. To better understand this variability, the positron emission tomography (PET) tracer [F]canagliflozin was developed via a Cu-mediated F-fluorination of its boronic ester precursor with a radiochemical yield of 2.0 ± 1.9% and a purity of >95%. The GMP automated synthesis originated [F]canagliflozin with a yield of 0.5-3% ( = 4) and a purity of >95%. Autoradiography showed [F]canagliflozin binding in human kidney sections containing SGLT2. Since [F]canagliflozin is the isotopologue of the extensively characterized drug canagliflozin and thus shares its toxicological and pharmacological characteristics, it enables its immediate use in patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631709 | PMC |
http://dx.doi.org/10.1021/acs.jmedchem.1c01269 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!